Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector
Sort by: Date|Relevance

Big news at the turn of the year! Nordex, Novo Nordisk, AJN Resources!

Is now the time for gold explorers? The price of gold remains firmly above USD 4,300 per ounce, and shares of gold producers are performing well, perhaps even a little too well. Investors looking to continue participating in the gold bull market may therefore turn their a...
Fabian Lorenz | December 23, 2025 |

Decoding patient data sets to help clinical trials succeed

How well do you know your clinical patients? What if there was a way to uncover the hidden relationship between patients in clinical trials empowering scientists to make critical decisions. Lyndsay Malchuk from Stockhouse Publishing recently sat down with NetraMark Hold...
Lyndsay Malchuk | March 3, 2025 |

NervGen Pharma: Proof that NVG-291 works?

It’s arguably a Eureka moment for investors in NervGen Pharma (TSX.V: NGEN) (OTCQB: NGENF). Tantalizing anecdotal “evidence” has just been published that suggests that NervGen’s prospective wonder-drug — NVG-29...
Knox Henderson | December 23, 2024 |

NervGen: Are amazing human trial results leaking out?

“We are very excited! We are very, very excited!” So says Dr. Monica Perez, who is running the first human trial for a potential new wonder drug being developed by a tiny but well-financed life sciences start-up, NervGen Pharma Corp. ...
Knox Henderson | July 2, 2024 |

Can NervGen keep a lid on explosive news?

Speculation of early “evidence” of successful proof-of-concept human trials sparks stock rallies Trial volunteers taking a placebo are offered the real deal in a follow-up trial as a “reward” The company&Clo...
Knox Henderson | March 20, 2024 |

Is this stunning 'evidence' that NervGen has the goods?

This could be the signal that tiny NervGen Pharma Corp. (TSX-V:NGEN; OTCQX:NGENF) is destined to be one of the top performing biotech startup stocks this year. It came in a seemingly innocuous podcast interview about the company’s ongoing Phase 1b/2...
Knox Henderson | February 1, 2024 |

NetraMark Holdings, bridging an important pharmaceutical industry gap

NetraMark Holdings is a tech company, looking to identify and fill current gaps in the pharmaceutical industry. The Toronto-based company offers its proprietary algorithms to change the way in which Artificial Intelligence is used in the field, uncovering insights fro...
Simon Druker | April 27, 2023 |

Shaping the Future of Medicine by Delivering Regenerative Medicines

(Click image to play video) Envision a chest pain that feels like the most severe form of heartburn you ever experienced before. This is one of the main symptoms of ischemia – a disease which millions of people around the globe live with every day. Treati...
Dave Jackson | December 8, 2020 |

Akero Therapeutics Shares Rise on Positive Data from Phase 2a NASH Study

Akero Therapeutics shares traded 28% higher and established a new 52-week high after the company reported that it recorded positive histological data across all Efruxifermin dosage groups in its Phase 2a BALANCED Study in NASH patients. Clinical-stage biotechnology...
Streetwise Reports | July 2, 2020 |

Regenerative Medicine Firm Reports Early Results from COVID-19 Trials

Pluristem Therapeutics' coronavirus clinical studies and financing are discussed in a Dawson James report. In a June 11 research note, Dawson James analyst Jason Kolbert reported that Pluristem Therapeutics Inc. (PSTI:NASDAQ) announced the status of COVID-19-infe...
Streetwise Reports | June 18, 2020 |
1 2 3 4 5